Collagenase clostridium hystolyticum in the management of Peyronie's disease

Affiliations

Editorial

Sun Tae Ahn et al. Transl Androl Urol. 2017 Apr.

. 2017 Apr;6(2):305-307.

doi: 10.21037/tau.2017.01.15.

¹ Department of Urology, Guro Hospital, Korea University College of Medicine, Seoul, Korea.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Yang KK, Bennett N. Yang KK, et al. Urology. 2016 Aug;94:143-7. doi: 10.1016/j.urology.2016.04.049. Epub 2016 May 17. Urology. 2016. PMID: 27211926

1. Tan RB, Sangkum P, Mitchell GC, et al. Update on medical management of Peyronie's disease. Curr Urol Rep 2014;15:415. 10.1007/s11934-014-0415-4 - DOI - PubMed
1. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74. 10.1111/j.1743-6109.2010.01850.x - DOI - PubMed
1. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10:135-40. 10.1007/BF00255956 - DOI - PubMed
1. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985;134:280-3. - PubMed
1. Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993;149:56-8. - PubMed